24087/34351US=80 / Biol/Mol
Alaoui-Jamali MA, Pinto D. Proteomic profiling of tyrosine kinases as pharmacological endpoints for targeted cancer therapy. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 59-77. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

TIROSINA-QUINASES PROTEICAS; CANCER; TERAPIA-ALVO; PROTEOMICA

24088/34351US=80 / Biol/Mol
Jain KK. Tumor proteomics: oncoproteomics for personalized management of cancer. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 81-99. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

MICROARRAYS DE PROTEINA; DROGAS ANTICANCER; BIOMARKETING; CANCER; ONCOPROTEOMICS; MEDICINA PERSONALIZADA; FARMACOGENOMICA; PHARMACOPROTEOMICS; PERFIL DE PROTEINAS; PROTEOMICA

24089/34351US=80 / Biol/Mol
Annunziata CM, Roque DM, Azad N, Kohn EC. Application of serum and tissue proteomics to understand and detect solid tumors. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 101-20. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

PROTEOMICA; ENSAIO CLINICO; TUMOR SOLIDO; ESPECTROMETRIA DE MASSA; TISSUE MICROARRAY

24090/34351US=80 / Biol/Mol
Sarto C, Proserpio V, Magni F, Mocarelli P. Insight on renal cell carcinoma proteome. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 121-37. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

CARCINOMA DE CELULAS RENAIS PROTEOMA; CARCINOMA DE CELULAS RENAIS; PROTEOMA; GENOMICA; BIOMARCADORES; ELECTROFORESE BIDIMENSIONAL; ANALISE SEROLOGICA PROTEOMA; MODIFICACAO POS-TRADUCAO

24091/34351US=80 / Biol/Mol
Reumond MA, Beshay M, Lippert H. Proteomics in lung cancer. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 139-59. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

PROTEOMICA NO CANCER DE PULMAO; CANCER DE PULMAO; PROTEOMICA; HNRNP; CITOQUERATINAS; LCM

24092/34351US=80 / Biol/Mol
Gjertsen BT, Sjoholt G. Proteomic strategies of therapeutic individualization and target discovery in acute myeloid leukemia. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 161-87. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

LEUCEMIA MIELOIDE AGUDA; BIOMARCADORES; PHARMACOPROTEOMICS; ACIDO TRANS-RETINOICO; INIBIDORES DE QUINASE DE TIROSINA; HISTONA DEACETILASE INIBIDORES; INIBIDORES DE PROTEASSOMA

24093/34351US=80 / Biol/Mol
Brünner N, Holten-Andersen M, Sweep F, Foekens J, Schmitt M, Duffy MJ. New tumor biomarkers. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 189-207. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

BIOMARCADORES TUMORAIS; PRE-ANALITICA VARIAVEIS; VARIAVEL ANALITICA; POS-ANALITICA VARIAVEL; MARCADORES DE DETECCAO DE MARCADORES DE TRIAGEM; MARCADORES PROGNOSTICOS; MARCADORES PREDITIVOS; MARCADORES DE MONITORAMENTO

24094/34351US=80 / Biol/Mol
Apweiler R, Mueller M. Bioinformatics and regulatory aspects of proteomics: annotating the human proteome. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 211-35. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

HUMANO; PROTEOMICA; ANOTACAO FUNCIONAL; INTEGRACAO DE DADOS; PADRONIZACAO DE DADOS

24095/34351US=80 / Biol/Mol
Li D, Hackett J, Chan M, Pennello G, Gutman S. Regulatory issues in the co-development of oncology drugs and proteomic tests: an overview. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 237-58. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

CANCER; PROTEOMICA; ALVO; AVALIACAO DE TERAPIA; REGULACAO

24096/34351US=84 / Biol/Mol
Jakowlew SB. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: component hardware for transformig growth factor-B signal transduction: TGF-B ligands, TGF-B receptors, and smads. In: ___. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 3-21. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TGF-B LIGANTES; TGF-B RECEPTORES; SMAD; TRANSDUCAO DE SINAL; PROLIFERACAO

24097/34351US=84 / Biol/Mol
Seoane J. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: component hardware for transformig growth factor-B signal transduction: TGF-B signaling in homeostasis and cancer. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 23-35. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TGF-B; SMAD; PROLIFERACAO; CANCER; TRANSDUCAO DE SINAL

24098/34351US=84 / Biol/Mol
Todorovic V, Rifkin DB. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: component hardware for transformig growth factor-B signal transduction: TGF-B availability: latent TGF-B and latent TGF-B binding proteins. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 37-55. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

FACTOR DE CRESCIMENTO TRANSFORMANTE-B; LATENCIA PROTEINA ASSOCIADA; LATENCIA ASSOCIADA PROTEINA LATENTE; PROTEINA TGF-B DE LIGACAO; MATRIZ EXTRACELULAR; PLASMINA; THROBOSPODIN-1

24099/34351US=84 / Biol/Mol
Hyytiäinen M, Koli K, Keski-Oja J. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: component hardware for transformig growth factor-B signal transduction: biological functions of latent TGF-B-binding and activation of TGF-B. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 57-75. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

LTBP; TGF-B; MATRIZ EXTRACELULAR; LATENCIA; ATIVACAO

24100/34351US=84 / Biol/Mol
Atfi A, Bourgeade MF. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: component hardware for transformig growth factor-B signal transduction: regulators of smad2/3 transcription and phosphorylation. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 77-90. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

FOSFORILACAO SMAD; TRANSLOCACAO NUCLEAR DE SMADS; ATIVIDADE TRANSCRICIONAL SMAD; COATIVADORES SMADS; SMADS COREPRESSORS

24101/34351US=84 / Biol/Mol
Kim SS, Shuman C, Mishra L. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: component hardware for transformig growth factor-B signal transduction: Interaction of smad4 and embryonic liver fodrin-B-spectrin in hyperplasia, neoplasia, and tumor suppression. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 91-103. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TGF-B; SMAD4; CAMUNDONGOS KNOCKOUT; TUMORIGENESE; FATOR TRANSFORMADOR DE CRESCIMENTO

24102/34351US=84 / Biol/Mol
Liu F. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: component hardware for transformig growth factor-B signal transduction: regulation of smad activity by phosphorylation. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 105-23. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TGF-B; SMAD; FOSFORILACAO; FOSFATASE; QUINASE DO RECEPTOR; MAP QUINASE; CDK; CANCER

24103/34351US=84 / Biol/Mol
Xu L. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: nuclear targeting of TGF-B-activated smads in normal and tumor biology. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 125-37. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

IMPORTACAO NUCLEAR; EXPORTACAO NUCLEAR; NUCLEO-CITOPLASMATICO; SMAD; TGF-B

24104/34351US=84 / Biol/Mol
Xu L. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: ski, snoN, and aKt as negative regulators of smad activity: balancing cell death and cell survival regulatorsnuclear targeting of TGF-B-activated smads in normal and tumor biology. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 139-53. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TGF-B; SMAD; SKI; SNON; AKT; TUMORIGENESE

24105/34351US=84 / Biol/Mol
Zhang YE, Yamashita M. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: transforming growth factor-B in cancer therapy: smurfs in TGF-B signaling and regulation of bone homeostasis and cancer. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 155-67. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

SMURF; SMAD; TGF-B; UBIQUITINA; E3 LIGASE; HECT DOMINIO

24106/34351US=84 / Biol/Mol
Jin Q, Gao G, Mulder KM. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: involvement of km23 dynein light chains in TGF B signaling. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 169-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

KM23; TGF-B; DINEINA; TRANSDUCAO DE SINAL; CANCER; FATOR DE CRESCIMENTO; PROTEINA MOTOR; DYNLRB; SMAD; TRAFICO

Primeira | Anterior | Próxima | Última